Cargando…

Editorial: Targeting MYCN in Pediatric Cancers

Detalles Bibliográficos
Autor principal:	Sala, Arturo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429566/ https://www.ncbi.nlm.nih.gov/pubmed/26029658 http://dx.doi.org/10.3389/fonc.2014.00330

Ejemplares similares

Targeting MYCN in Pediatric and Adult Cancers
por: Liu, Zhihui, et al.
Publicado: (2021)

Editorial: Molecular Mechanisms and Treatment of MYCN-Driven Tumors
por: Suenaga, Yusuke, et al.
Publicado: (2021)

MYCN and the epigenome
por: He, Stanley, et al.
Publicado: (2013)

Molecular Mechanisms of MYCN Dysregulation in Cancers
por: Liu, Ruochen, et al.
Publicado: (2021)

Targeting MYCN in Molecularly Defined Malignant Brain Tumors
por: Borgenvik, Anna, et al.
Publicado: (2021)

Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer
por: Cage, Tene Aneka, et al.
Publicado: (2015)

MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma
por: Liu, Tao, et al.
Publicado: (2022)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers
por: Takatori, Atsushi, et al.
Publicado: (2021)

CT-Based Radiomics Signature With Machine Learning Predicts MYCN Amplification in Pediatric Abdominal Neuroblastoma
por: Chen, Xin, et al.
Publicado: (2021)

Reciprocal Induction of MDM2 and MYCN in Neural and Neuroendocrine Cancers
por: Tran, Hung N., et al.
Publicado: (2020)

MYCN: from oncoprotein to tumor-associated antigen
por: Pistoia, Vito, et al.
Publicado: (2012)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

Control Analysis of Protein-Protein Interaction Network Reveals Potential Regulatory Targets for MYCN
por: Pan, Chunyu, et al.
Publicado: (2021)

Non-Genomic Control of Dynamic MYCN Gene Expression in Liver Cancer
por: Qin, Xian-Yang, et al.
Publicado: (2021)

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma
por: Petroni, Marialaura, et al.
Publicado: (2012)

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
por: Chen, Lindi, et al.
Publicado: (2012)

ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma
por: Huynh, Tony, et al.
Publicado: (2012)

MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin
por: Gherardi, Samuele, et al.
Publicado: (2013)

Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead
por: Shrestha, Sumana, et al.
Publicado: (2021)

Editorial: Molecular Diagnostics of Pediatric Cancer
por: He, Jing, et al.
Publicado: (2021)

The Role of MYCN in Symmetric vs. Asymmetric Cell Division of Human Neuroblastoma Cells
por: Izumi, Hideki, et al.
Publicado: (2020)

MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma
por: Raieli, Salvatore, et al.
Publicado: (2021)

Clinical value of (18)F-FDG PET/CT to predict MYCN gene, chromosome 1p36 and 11q status in pediatric neuroblastoma and ganglioneuroblastoma
por: Ren, Jiazhong, et al.
Publicado: (2023)

Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified Neuroblastoma
por: Bellamy, Jacob, et al.
Publicado: (2020)

MYCN is a novel oncogenic target in pediatric T-cell Acute Lymphoblastic Leukemia
por: Astolfi, Annalisa, et al.
Publicado: (2013)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN)
por: Tauziède-Espariat, A., et al.
Publicado: (2019)

Editorial: Nanomedicine in Cancer Targeting and Therapy
por: Longo, João Paulo Figueiró, et al.
Publicado: (2021)

Editorial: Engineered Targeted Cancer Immunotherapies
por: Fantini, Massimo, et al.
Publicado: (2022)

Editorial: Targeting Estrogens in Cancer Care
por: Di Donato, Marzia
Publicado: (2022)

A Novel Mechanism of 17-AAG Therapeutic Efficacy on HSP90 Inhibition in MYCN-Amplified Neuroblastoma Cells
por: Hanna, Reine, et al.
Publicado: (2021)

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma
por: Keller, Kaylee M., et al.
Publicado: (2022)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

Immunotherapy Targets in Pediatric Cancer
por: Orentas, Rimas J., et al.
Publicado: (2012)

PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc
por: Li, Zhiheng, et al.
Publicado: (2020)

Editorial: Targeting Pancreatic Cancer: Strategies and Hopes
por: Manu, Kanjoormana Aryan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0o4ohf1eookoc9u2l1qb3oglk1